homepage-top-section

The partnership will particularly focus on identifying composite biomarkers, which integrate several biological entities into a single readout. This identification will help guide therapeutic decision making. Gastroesophageal cancer

The collaboration will use the companies’ respective strengths to support the development of ASO-based precision medicine therapies and for creating compelling value opportunities for Vanda and OliPass. It

This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human

As part of the collaboration deal, the companies will use ArsenalBio’s T cells screening and engineering technology for identifying the critical success circuits in T cell-based therapies. Genentech,

Retevmo (selpercatinib, 40 mg & 80 mg capsules) is indicated to treat locally advanced or metastatic solid tumours in adult patients with a rearranged during transfection (RET) gene

As part of the partnership deal, the entities will initially plan to conduct a preclinical proof-of-concept efficacy study with the new radio-conjugate targeting Netrin-1, combining Netris’ NP137 with

The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen

Yescarta is a chimeric antigen receptor (CAR) T-cell therapy that is indicated to treat diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients whose

Under the deal terms, NeuroBo will undertake the development, regulatory and commercial works for the two therapies across the world excluding certain Asian-Pacific areas. Dong-A will be responsible